Accéder au contenu
Merck
  • Corneal cross-linking in keratoconus using the standard and rapid treatment protocol: differences in demarcation line and 12-month outcomes.

Corneal cross-linking in keratoconus using the standard and rapid treatment protocol: differences in demarcation line and 12-month outcomes.

Investigative ophthalmology & visual science (2014-12-04)
Sara Brittingham, Christoph Tappeiner, Beatrice E Frueh
RÉSUMÉ

To compare the occurrence rate and depth of the demarcation line and topographical outcome after corneal cross-linking (CXL) for keratoconus using two different treatment protocols. A retrospective analysis of 131 eyes with progressive keratoconus treated with CXL using riboflavin and UV-A was performed. Eyes were treated either with the standard Dresden protocol (30 minutes irradiation, 3 mW/cm(2), UV-XTM 1000) or a rapid protocol (10 minutes irradiation, 9 mW/cm(2), UV-XTM 2000). The presence and depth of the corneal demarcation line was assessed with an anterior segment optical coherence tomography device 1 month after CXL by a masked observer. Corneal topography and tomography was performed at baseline and at 12-month follow-up with Pentacam and the TMS (Topographic Modeling System) device. In the standard protocol group, 76.5% (62/81) of treated corneas revealed a demarcation line 1 month after CXL, whereas such a demarcation line was observed in only 22% (11/50) of eyes treated with the rapid protocol (P < 0.0001). The demarcation line was significantly more superficial in the rapid protocol group (P = 0.004). Corneal topography values between baseline and 12 months after CXL showed a mean change of -0.76 diopters (D) in Kmax (SD ± 2.7) in the standard protocol group versus a mean change of +0.72 D in Kmax (SD ± 1.5) in the rapid protocol (P = 0.007). The rapid CXL protocol negatively influences the occurrence and depth of the demarcation line 1 month after CXL. Our results show a negative effect on the topographical outcome 1 year after CXL.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Fluorometholone, ≥98%
Sigma-Aldrich
Tetracaine hydrochloride, ≥99%
USP
Fluorometholone, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
β-D-Allose, rare aldohexose sugar
USP
Tetracaine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Supelco
Tetracaine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Tetracaine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Tetracaine for system suitability, European Pharmacopoeia (EP) Reference Standard